Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
New Managers January 2014

Editorial

Dear Opalesque Reader,

Welcome back to New Managers' new user-friendly, real time format!

2014's first issue of New Managers starts with a list of the New Launches in the hedge fund arena, a roundup of the latest manager news in Emerging Manager Bulletin, and the latest seeding developments at Deutsche, NewAlpha and SkyBridge in Seeder's Corner.

Ian Hamilton discusses the probable return of the hedge fund investor and the debatable necessity of regulation and reporting in the first installment of his new monthly column, the Scotstone Column.

In Fund Profiles, Shorepath Capital's manager talks about a new long-biased equity fund, MitonOptimal's about an upcoming commodities CTA, and Blueshift Capital's about a six-month old volatility fund.

We have the customary review of the latest news, views and findings relevant to the space in News & Perspectives, and a review of the latest products and services useful to emerging hedge funders in Servicers' Spot.

Don't forget, subscribers can access past issues of New Managers in Opalesque's Archive here: http://www.opalesque.com/Archive-New-Managers.html.

Please do contact me if you have any news or views or if you want to contribute. Wishing you a Happy 2014!

Benedicte Gravrand Editor gravrand@opalesque.com Benedicte Gravrand

Opalesque New Managers is edited by Benedicte Gravrand. Based near Geneva, Benedicte also writes exclusive stories and special reports for Opalesque's daily hedge fund publication, the Alternative Market Briefing (AMB), and occasionally moderates ......................

To view our full article please login

This article was published in Opalesque's New Managers a top-down monthly analysis, news and research publication on the global emerging manager space.
New Managers
New Managers
New Managers

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for